265 followers
Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial https://t.co/h6WhypjKtH
Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial https://t.co/h6WhypjKtH
RT @DanielJDrucker: Lessons from AMPLITUDE-O. Titrating efpeglenatide and potentially other glucagon-like peptide-1 receptor agonists to op…
RT @CircAHA: #ICYMI: Efpeglenatide Dose and CV Outcomes in Diabetes @PHRIresearch #AHAJournals
RT @CircAHA: #ICYMI: Efpeglenatide Dose and CV Outcomes in Diabetes @PHRIresearch #AHAJournals